Clinical N stage as a predictor of PCR to neoadjuvant chemoimmunotherapy in NSCLC: a real-world cohort study

Abstract This study assessed the efficacy of neoadjuvant chemoimmunotherapy (NACI) in patients with driver gene-negative stage IIA-IIIB non-small cell lung cancer. In a single-center retrospective cohort of 173 patients who completed NACI and underwent surgical resection, clinicopathological data were evaluated using univariate and multivariate logistic regression analyses and visualization methods. In this surgically resected cohort, the overall pathological complete response (pCR) rate was 38.7%. Among the available clinicopathological variables, cN2-3 stage was independently associated with a significantly lower pCR rate compared with cN0 ( OR = 0.387, 95% CI : 0.161–0.933, P = 0.035). This association remained significant in the lung squamous cell carcinoma subgroup ( OR = 0.366, 95% CI : 0.141–0.950, P = 0.039), whereas no significant association was observed in the smaller lung adenocarcinoma subgroup in exploratory analyses. No significant associations were observed with gender, age, pathological type, cT stage, or number of treatment cycles in the multivariate analyses. Exploratory subgroup analysis suggested that among patients with cN2-3, those who achieved pCR appeared to have a lower primary tumor burden (cT1-2) and more treatment cycles (3-4), although these associations were not statistically significant. These findings suggest that NACI achieved a relatively high pCR rate in this population and that cN stage was independently associated with treatment response among the available clinicopathological variables. However, these results should be considered exploratory because residual and unmeasured confounding cannot be excluded. Moreover, the heterogeneity among patients with cN2-3 disease should be further examined by integrating cT stage and treatment cycles to identify potentially responsive subgroups, pending prospective validation.

Authors

Institutions

Publication Details

Journal
World Journal of Surgical Oncology
Published
2026-11-17
DOI
https://doi.org/10.1186/s12957-026-04640-9
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical N stage as a predictor of PCR to neoadjuvant chemoimmunotherapy in NSCLC: a real-world cohort study

Shoukai Zong, Min Gao, Chuankun Peng, Jialu Hu et al.
7 links
World Journal of Surgical Oncology
Lung Cancer Diagnosis and Treatment
article

Clinical N stage as a predictor of PCR to neoadjuvant chemoimmunotherapy in NSCLC: a real-world cohort study

Shoukai Zong, Min Gao, Chuankun Peng, Jialu Hu, Wenjuan Qi, Jing Dong, Wanjun Xu
article en

Abstract

Abstract This study assessed the efficacy of neoadjuvant chemoimmunotherapy (NACI) in patients with driver gene-negative stage IIA-IIIB non-small cell lung cancer. In a single-center retrospective cohort of 173 patients who completed NACI and underwent surgical resection, clinicopathological data were evaluated using univariate and multivariate logistic regression analyses and visualization methods. In this surgically resected cohort, the overall pathological complete response (pCR) rate was 38.7%. Among the available clinicopathological variables, cN2-3 stage was independently associated with a significantly lower pCR rate compared with cN0 ( OR = 0.387, 95% CI : 0.161–0.933, P = 0.035). This association remained significant in the lung squamous cell carcinoma subgroup ( OR = 0.366, 95% CI : 0.141–0.950, P = 0.039), whereas no significant association was observed in the smaller lung adenocarcinoma subgroup in exploratory analyses. No significant associations were observed with gender, age, pathological type, cT stage, or number of treatment cycles in the multivariate analyses. Exploratory subgroup analysis suggested that among patients with cN2-3, those who achieved pCR appeared to have a lower primary tumor burden (cT1-2) and more treatment cycles (3-4), although these associations were not statistically significant. These findings suggest that NACI achieved a relatively high pCR rate in this population and that cN stage was independently associated with treatment response among the available clinicopathological variables. However, these results should be considered exploratory because residual and unmeasured confounding cannot be excluded. Moreover, the heterogeneity among patients with cN2-3 disease should be further examined by integrating cT stage and treatment cycles to identify potentially responsive subgroups, pending prospective validation.

World Journal of Surgical Oncology
North China University of Science and Technology (CN), People’s Hospital of Rizhao (CN), Shandong Tumor Hospital (CN), Zoucheng People's Hospital (CN), Shandong First Medical University (CN), Gaozhou People's Hospital (CN), Tangshan Gongren Hospital (CN)
National Natural Science Foundation of China, Wu Jieping Medical Foundation
Good health and well-being
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon